BioMedNewsBreaks – Silo Pharma Inc. (SILO) Initiates Coverage with InvestorBrandNetwork

March 30, 2022 10:54:36

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has partnered with InvestorBrandNetwork (“IBN”) for its corporate communications. IBN is a multifaceted financial news and publishing company focused on private and public entities. Silo works to develop innovative solutions that address serious conditions such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease and other rare neurological disorders. The company is committed to identifying and partnering with leading medical universities; SILO provides invaluable financial resources to develop safe therapeutic treatments while advancing research through clinical stage studies and trials and into commercialization. The company has partnered with multiple leading medical universities, including Maastricht University, the University of California San Francisco, the University of Maryland, Baltimore, and Columbia University. According to the announcement, IBN will leverage its newsletter, social media channels, wire services and investor-based distribution network of 5,000 syndication outlets to provide coverage of Silo Pharma. “Through partnerships with world-class medical research partners, Silo is uniquely positioned to drive significant advances in the medical and psychedelic space,” said IBN director of client solutions Chris Johnson in the press release. “We’re excited to customize our comprehensive suite of corporate communications solutions for the company as it works alongside its partners to develop innovative solutions that improve the lives of people impacted by a number of currently underserved conditions.”

To view the full press release, visit


Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Alzheimer’s, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which the company believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork